Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting

News provided by

Mar 25, 2019, 19:00 ET

ROCKVILLE, Md. and HONG KONG, March 25, 2019 /PRNewswire/ -- Ascentage Pharma, globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases, today announced that research results of its pipeline of small molecule therapeutics will be presented at the 2019 American Association for Cancer Research (AACR) annual meeting in Atlanta, March 29-April 3, 2019.

AACR abstracts include:

Title: Predicting Drug Sensitivity to A Novel BCL-2 and BCL-xL Dual Inhibitor In Solid Tumor PDX Trials
Session Title: BCL-2 Family Proteins
Session Date and Time: Monday, April 1, 2019 1:00 PM - 5:00 PM EDT
Poster Number: 2503
Title: MDM2 Inhibitor APG-115 Synergizes With CDK4/6 Inhibitors In A Patient Derived Xenograft Model of Dedifferentiated Liposarcoma
Session Title: Credentialing of Molecular Targets
Session Date and Time: Monday, April 1, 2019 8:00 AM – 12:00 PM EDT
Poster Number: 1253
Title: Activation of P53 In the Tumor Microenvironment by MDM2 Inhibitor APG-115 Synergizes With PD-1 Blockade Independently of P53 Status of Tumor Cells
Session Title: Combination Immunotherapies 2
Session Date and Time: Tuesday, April 2, 2019 8:00 AM - 12:00 PM EDT
Poster Number: 3192
Title: BCL-2 Selective Inhibitor APG-2575 Synergizes with BTK Inhibitor in Preclinical Xenograft Models of Follicular Lymphoma and diffuse Large B-cell Lymphoma
Session Title: Apoptosis, Necrosis, and Cancer Cell Survival
Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM EDT
Poster Number: 2058
Title: Synergistic Effect of BCL-2 Inhibitor APG-2575 and CDK9 Inhibitor in Acute Myeloid Leukemia and DLBCL Preclinical Tumor Models
Session Title: Novel Antitumor Agents 1
Session Date and Time: Tuesday, April 2, 2019 8:00 AM – 12:00 PM EDT
Poster Number: 3068
Title: FAK Blockade Enhances Antitumor Effect of BTK Inhibitor In Esophageal Squamous Cell Carcinoma via EGFR-ERK-Akt Pathway Inhibition
Session Title: Combination Approaches to Novel Therapies
Session Date and Time: Sunday, March 31, 2019 1:00 PM – 5:00 PM EDT
Poster Number: 309
Title: A Novel Bcl-2/Bcl-XL Inhibitor APG-1252-12A as A Potential Therapeutic Strategy for Gastric Carcinoma
Session Title: Apoptosis, Necrosis, and Cancer Cell Survival
Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM EDT
Poster Number:2054
Title: FAK Inhibition Reduces Tumor Infiltration of Tregs Via Restricting CCL5 Release and Boosts the Present Therapeutic Regimen for BRAF^V600E -mutated Colorectal Carcinoma
Session Title: Immunomodulation by Chemotherapy and Targeted Agents
Session Date and Time: Tuesday, April 2, 2019 1:00 PM – 5:00 PM EDT
Poster Number: 3958
Title: Novel FAK/ALK/ROS1 Inhibitor APG-2449 Synergizes with Osimertinib in Preclinical Xenograft Models of EGFR-mutant NSCLC
Session Title: Tyrosine Kinase and Phosphatase Inhibitors 2
Session Date and Time: Monday, April 1 2019 1:00 PM – 5:00 PM EDT
Poster Number: 2204

About Ascentage Pharma
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. The Company's expertise is in developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. Ascentage has built a rich pipeline of eight clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.

Media Contact

Hill+Knowlton Strategies (Hong Kong)
Joanne Lam / Morning Zhu
Tel: +852 2894 6211 / 2894 6227
Email: [email protected] / [email protected]

SOURCE Ascentage Pharma